-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, A3w2rTgrNCW1ePtzBvqX5Ab+pwYKftCPi+mLLDwL5jT+4Y1y7s1mRfoC11FLqoSU ZeRNP8TNkW/YcQXheRSs9g== 0000912057-00-054428.txt : 20001222 0000912057-00-054428.hdr.sgml : 20001222 ACCESSION NUMBER: 0000912057-00-054428 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20001221 ITEM INFORMATION: FILED AS OF DATE: 20001221 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: SEC FILE NUMBER: 000-19319 FILM NUMBER: 793334 BUSINESS ADDRESS: STREET 1: 130 WAVERLY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139-4242 BUSINESS PHONE: 6165776000 8-K 1 a2033910z8-k.txt 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of report (Date of earliest event reported): December 21, 2000 VERTEX PHARMACEUTICALS INCORPORATED (Exact name of registrant as specified in its charter) Massachusetts (State of incorporation) 000-19319 04-3039129 (Commission File No.) (IRS Employer Identification No.) 130 Waverly Street Cambridge, MA 02139 (Address of principal executive offices and zip code) Registrant's telephone number, including area code: (617) 577-6000 Item 5. OTHER EVENTS Richard H. Aldrich has resigned his position as Senior Vice President and Chief Business Officer of Vertex Pharmaceuticals Incorporated. Mr. Aldrich will continue to have a role at Vertex, reporting to Joshua Boger, Ph.D., Chairman and CEO, on issues of strategy, business development and collaborations. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VERTEX PHARMACEUTICALS INCORPORATED Dated: December 21, 2000 By: /s/ Joshua S. Boger ----------------------------- Joshua S. Boger CEO -----END PRIVACY-ENHANCED MESSAGE-----